Chung Hun Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chung Hun Lee has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Sang Sik Choi
Department of Anesthesiology and Pain Medicine, Korea University Medical Center, Guro Hospital, Seoul, Republic of Korea
7 shared publications Sang Sik Choi
Korea Univ, Med Ctr, Guro Hosp, Dept Anesthesiol & Pain Med, 148 Gurodong Rd, Seoul 08308, South Korea
4 shared publications- Hee Yong Kang
Department of Anesthesiology and Pain Medicine, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Seoul 02447, Republic of Korea
3 shared publications Heezoo Kim
Korea Univ, Med Ctr, Guro Hosp, Dept Anesthesiol & Pain Med, 148 Gurodong Rd, Seoul 08308, South Korea
3 shared publications- Heezoo Kim
Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea
3 shared publications - Mi Kyoung Lee
Department of Anesthesiology and Pain Medicine, Korea University Medical Center, Guro Hospital, Gurodong Road 148, Guro-Gu, Seoul 08308, Korea
3 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1734
Short-Term Physicochemical and Colloidal Behavior of Dexamethasone Palmitate Admixed with Local Anesthetics
Background/Objectives: Dexamethasone palmitate (DXP) is a corticosteroid prodrug formulated as an oil-in-water lipid emulsion. We investigated its short-term physicochemical and colloidal behavior when admixed with local anesthetics (LAs). Methods: Seven DXP–LA mixtures containing ropivacaine, lidocaine, or bupivacaine (stress-test or clinically relevant preparations) were stored in polypropylene syringes at 24 °C and assessed at 0, 1, and 2 h (n = 5) by visual inspection, optical microscopy with blinded scoring, dynamic and electrophoretic light scattering, pH, and high-performance liquid chromatography. Results: No visible precipitation or phase separation occurred. Microscopy revealed time-dependent aggregation-like changes, most pronounced in saline-diluted ropivacaine and bupivacaine mixtures (interobserver weighted κ = 0.954). Bulk particle-size metrics showed no consistent corresponding increase. The maximum pH change was 0.178 units, and parent-drug concentrations remained at 97.86–99.63% of baseline. Zeta-potential results were variable. Conclusions: Despite no overt incompatibility over 2 h, microscopy-detectable changes were not consistently reflected in bulk particle-size metrics or parent-drug concentrations. Without matched DXP-alone and saline-diluted DXP controls, whether these changes require the LA or arise from dilution of the emulsion alone could not be determined. These findings do not establish emulsion stability or clinical safety; further in vitro and in vivo studies are needed.
- 1 November 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (11) , 1734
Open AccessShort-Term Physicochemical and Colloidal Behavior of Dexamethasone Palmitate Admixed with Local Anesthetics
Background/Objectives: Dexamethasone palmitate (DXP) is a corticosteroid prodrug formulated as an oil-in-water lipid emulsion. We investigated its short-term physicochemical and colloidal behavior when admixed with local anesthetics (LAs). Methods: Seven DXP–LA mixtures containing ropivacaine, lidocaine, or bupivacaine (stress-test or clinically relevant preparations) were stored in polypropylene syringes at 24 °C and assessed at 0, 1, and 2 h (n = 5) by visual inspection, optical microscopy with blinded scoring, dynamic and electrophoretic light scattering, pH, and high-performance liquid chromatography. Results: No visible precipitation or phase separation occurred. Microscopy revealed time-dependent aggregation-like changes, most pronounced in saline-diluted ropivacaine and bupivacaine mixtures (interobserver weighted κ = 0.954). Bulk particle-size metrics showed no consistent corresponding increase. The maximum pH change was 0.178 units, and parent-drug concentrations remained at 97.86–99.63% of baseline. Zeta-potential results were variable. Conclusions: Despite no overt incompatibility over 2 h, microscopy-detectable changes were not consistently reflected in bulk particle-size metrics or parent-drug concentrations. Without matched DXP-alone and saline-diluted DXP controls, whether these changes require the LA or arise from dilution of the emulsion alone could not be determined. These findings do not establish emulsion stability or clinical safety; further in vitro and in vivo studies are needed.
- Open Access
- 24 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (17) , e48493
Concomitant osteoporotic vertebral compression fracture and infectious spondylitis in a patient with herpes zoster: A case report
Rationale: The incidences of herpes zoster, osteoporotic vertebral compression fractures, and infectious spondylitis is increasing worldwide owing to the aging population. Given the potential for multiple comorbid conditions with overlapping clinical presentations, thorough history-taking and physical examination are essential for accurate diagnoses. However, the coexistence of herpes zoster, osteoporotic vertebral compression fractures, and infectious spondylitis in a single patient is exceedingly rare, making timely diagnosis even more challenging. Patient concerns: A 64-year-old woman with a medical history of hypertension, asthma, and right-sided hemiplegia secondary to a previous hemorrhagic stroke presented with painful vesicular lesions in the right T10 dermatome consistent with herpes zoster. Despite antiviral and antibiotic therapy, her pain worsened, and inflammatory markers increased significantly. Diagnoses: Physical examination revealed midline spinal tenderness and pain, exacerbated by postural changes. Magnetic resonance imaging confirmed a collapsed L3 vertebral body consistent with Kummell’s disease, along with paravertebral soft tissue changes and psoas muscle involvement, suggesting coexisting infectious spondylitis. Interventions: Although the biopsy cultures were negative, empirical intravenous cefazolin therapy was initiated. After 2 weeks of intravenous antibiotic treatment, the C-reactive protein and procalcitonin levels normalized. Given the persistent mechanical back pain and stabilized infection, a vertebroplasty was performed. Outcomes: After the vertebroplasty, the patient experienced rapid pain relief without any signs of recurrent infection. Following a 5-week course of intravenous antibiotic therapy and an additional 2 months of oral administration, the patient achieved complete clinical resolution with full remission of both infectious manifestations and zoster-associated sequelae. Lessons: This case underscores the importance of a comprehensive clinical assessment in older patients, even when a diagnosis of herpes zoster is apparent. Persistent or atypical symptoms warrant further evaluation to exclude concurrent diseases. Furthermore, vertebroplasty can be safely performed in select patients with infectious spondylitis following adequate antibiotic therapy, leading to pain reduction. A multidisciplinary, individualized approach is essential to achieve optimal outcomes in patients with complex spinal pathologies.
- 24 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (17) , e48493
Open AccessConcomitant osteoporotic vertebral compression fracture and infectious spondylitis in a patient with herpes zoster: A case report
Rationale: The incidences of herpes zoster, osteoporotic vertebral compression fractures, and infectious spondylitis is increasing worldwide owing to the aging population. Given the potential for multiple comorbid conditions with overlapping clinical presentations, thorough history-taking and physical examination are essential for accurate diagnoses. However, the coexistence of herpes zoster, osteoporotic vertebral compression fractures, and infectious spondylitis in a single patient is exceedingly rare, making timely diagnosis even more challenging. Patient concerns: A 64-year-old woman with a medical history of hypertension, asthma, and right-sided hemiplegia secondary to a previous hemorrhagic stroke presented with painful vesicular lesions in the right T10 dermatome consistent with herpes zoster. Despite antiviral and antibiotic therapy, her pain worsened, and inflammatory markers increased significantly. Diagnoses: Physical examination revealed midline spinal tenderness and pain, exacerbated by postural changes. Magnetic resonance imaging confirmed a collapsed L3 vertebral body consistent with Kummell’s disease, along with paravertebral soft tissue changes and psoas muscle involvement, suggesting coexisting infectious spondylitis. Interventions: Although the biopsy cultures were negative, empirical intravenous cefazolin therapy was initiated. After 2 weeks of intravenous antibiotic treatment, the C-reactive protein and procalcitonin levels normalized. Given the persistent mechanical back pain and stabilized infection, a vertebroplasty was performed. Outcomes: After the vertebroplasty, the patient experienced rapid pain relief without any signs of recurrent infection. Following a 5-week course of intravenous antibiotic therapy and an additional 2 months of oral administration, the patient achieved complete clinical resolution with full remission of both infectious manifestations and zoster-associated sequelae. Lessons: This case underscores the importance of a comprehensive clinical assessment in older patients, even when a diagnosis of herpes zoster is apparent. Persistent or atypical symptoms warrant further evaluation to exclude concurrent diseases. Furthermore, vertebroplasty can be safely performed in select patients with infectious spondylitis following adequate antibiotic therapy, leading to pain reduction. A multidisciplinary, individualized approach is essential to achieve optimal outcomes in patients with complex spinal pathologies.
- Open Access
- 27 March 2026
- Published by Korean Pain Society in The Korean Journal of Pain
- Vol. 39 (2) , 171-190
Clinical practice guidelines for the management of refractory postherpetic neuralgia by the Korean Pain Society
Hee Yong Kang, Chung Hun Lee, Doo-Hwan Kim, Yeon-Dong Kim, Won-Joong Kim, Eunsoo Kim, Jae Hun Kim, Hyun Jung Kim, Yangki Minn, Kyungseung Yang, Jinyoung Oh, Yongjae Yoo, So Young Lim, Mihn-Sook Jue, Eun Joo Choi, Kunhee Han, and Seong-Soo Choi. Korean J Pain -0001;0:. https://doi.org/10.3344/kjp.25161
- 27 March 2026
- Published by Korean Pain Society in The Korean Journal of Pain
- Vol. 39 (2) , 171-190
Open AccessClinical practice guidelines for the management of refractory postherpetic neuralgia by the Korean Pain Society
Hee Yong Kang, Chung Hun Lee, Doo-Hwan Kim, Yeon-Dong Kim, Won-Joong Kim, Eunsoo Kim, Jae Hun Kim, Hyun Jung Kim, Yangki Minn, Kyungseung Yang, Jinyoung Oh, Yongjae Yoo, So Young Lim, Mihn-Sook Jue, Eun Joo Choi, Kunhee Han, and Seong-Soo Choi. Korean J Pain -0001;0:. https://doi.org/10.3344/kjp.25161
- Open Access
- 1 April 2025
- Published by Korean Pain Society in The Korean Journal of Pain
- Vol. 38 (2) , 103-115
Physicochemical stability of mixtures of non-steroidal anti-inflammatory drugs such as ketorolac and diclofenac and antiemetics such as ondansetron and ramosetron: an in vitro study
Chung Hun Lee. Korean J Pain 2025;38:103-15. https://doi.org/10.3344/kjp.24316
- 1 April 2025
- Published by Korean Pain Society in The Korean Journal of Pain
- Vol. 38 (2) , 103-115
Open AccessPhysicochemical stability of mixtures of non-steroidal anti-inflammatory drugs such as ketorolac and diclofenac and antiemetics such as ondansetron and ramosetron: an in vitro study
Chung Hun Lee. Korean J Pain 2025;38:103-15. https://doi.org/10.3344/kjp.24316
- Open Access
Efficacy of Botulinum Type A Injection for the Treatment of Postherpetic Neuralgia and Pruritus Persisting for More Than Four Years—A Case Report
Background: Postherpetic neuralgia (PHN) and postherpetic pruritus (PHP) are common complications of shingles that affect patients’ quality of life. PHN and PHP can be managed using various medications and interventional procedures; however, complications persisting for at least six months may hamper recovery. Subcutaneous injections of botulinum toxin type A (BTX-A) can control persistent PHN and PHP. Case presentation: A 71-year-old man presented at our hospital with itching and pain. He had been diagnosed with shingles in the ophthalmic branch of the trigeminal nerve one year previously. As the pain and itching persisted despite medication, a supraorbital nerve block, Gasserian ganglion block, epidural nerve block, and radiofrequency thermocoagulation were performed. A subcutaneous injection of BTX-A was administered into the ophthalmic area of the trigeminal nerve three years after the initial presentation. A decrease of >80% in pain and itching was reported after the injection; however, the left eyelid drooped and the eyeball shifted downward and outward immediately after the injection. No deterioration in vision or pupil dilation was observed, and almost complete resolution of these symptoms occurred spontaneously three months after the injection. Pain and itching continued to improve without further side-effects until six months after the injection. Conclusions: The subcutaneous injection of BTX-A may be an alternative treatment option for chronic and refractory neurological diseases such as PHN and PHP, which persist for four years and are resistant to conventional treatments. Nevertheless, care must be taken to minimize the risk of ptosis.
Open AccessEfficacy of Botulinum Type A Injection for the Treatment of Postherpetic Neuralgia and Pruritus Persisting for More Than Four Years—A Case Report
Background: Postherpetic neuralgia (PHN) and postherpetic pruritus (PHP) are common complications of shingles that affect patients’ quality of life. PHN and PHP can be managed using various medications and interventional procedures; however, complications persisting for at least six months may hamper recovery. Subcutaneous injections of botulinum toxin type A (BTX-A) can control persistent PHN and PHP. Case presentation: A 71-year-old man presented at our hospital with itching and pain. He had been diagnosed with shingles in the ophthalmic branch of the trigeminal nerve one year previously. As the pain and itching persisted despite medication, a supraorbital nerve block, Gasserian ganglion block, epidural nerve block, and radiofrequency thermocoagulation were performed. A subcutaneous injection of BTX-A was administered into the ophthalmic area of the trigeminal nerve three years after the initial presentation. A decrease of >80% in pain and itching was reported after the injection; however, the left eyelid drooped and the eyeball shifted downward and outward immediately after the injection. No deterioration in vision or pupil dilation was observed, and almost complete resolution of these symptoms occurred spontaneously three months after the injection. Pain and itching continued to improve without further side-effects until six months after the injection. Conclusions: The subcutaneous injection of BTX-A may be an alternative treatment option for chronic and refractory neurological diseases such as PHN and PHP, which persist for four years and are resistant to conventional treatments. Nevertheless, care must be taken to minimize the risk of ptosis.
- 1 January 2024
- Vol. 27 (1) , E89-E98
Physicochemical Stability and Compatibility of Mixtures of Ropivacaine with Dexamethasone or Betamethasone for Epidural Steroid Injections: An In Vitro Study
Background: Epidural steroid injections are widely used to treat spinal and radiating pain. However, crystal formation has recently been reported in mixtures of ropivacaine and nonparticulate steroids, commonly used in epidural steroid injections. Objectives: Our study assessed the physicochemical stability of mixtures of different nonparticulate steroids and ropivacaine and aimed to propose a safe regimen for epidural steroid injections. Study Design: An in vitro protocol was used to examine the physicochemical stability of epidural steroid injection mixtures most commonly used at our institution. Setting: In vitro laboratory study. Methods: Twelve solutions were prepared by mixing 0.75% or 0.2% ropivacaine with dexamethasone or betamethasone at volume ratios of 1:1, 2:1, and 3:1 in propylene syringes at 24(degrees)C. The physical properties of the mixtures were observed with the naked eye and under a microscope, and their pH was measured. The concentration of each drug in the mixture was evaluated using high-performance liquid chromatography. Results: None of the ropivacaine and dexamethasone mixtures showed macroscopic or microscopic crystal formation after 2 hours, and there were no significant changes in pH. The concentrations of the 2 drugs remained stable for up to 2 hours. In contrast, at least 10 mu m crystals were observed microscopically and macroscopically in all mixtures of ropivacaine and betamethasone; the ropivacaine concentration was reduced by > 10% after one hour. Limitations: Confirming the stability of drugs in vitro does not ensure that their pharmacokinetics and pharmacodynamics remain unaltered in vivo. Conclusion: The combination of ropivacaine and betamethasone should be avoided because of their physicochemical instability. Combinations of ropivacaine and dexamethasone should be administered cautiously because they are more physicochemically stable than combinations of ropivacaine and betamethasone.
- 1 January 2024
- Vol. 27 (1) , E89-E98
Physicochemical Stability and Compatibility of Mixtures of Ropivacaine with Dexamethasone or Betamethasone for Epidural Steroid Injections: An In Vitro Study
Background: Epidural steroid injections are widely used to treat spinal and radiating pain. However, crystal formation has recently been reported in mixtures of ropivacaine and nonparticulate steroids, commonly used in epidural steroid injections. Objectives: Our study assessed the physicochemical stability of mixtures of different nonparticulate steroids and ropivacaine and aimed to propose a safe regimen for epidural steroid injections. Study Design: An in vitro protocol was used to examine the physicochemical stability of epidural steroid injection mixtures most commonly used at our institution. Setting: In vitro laboratory study. Methods: Twelve solutions were prepared by mixing 0.75% or 0.2% ropivacaine with dexamethasone or betamethasone at volume ratios of 1:1, 2:1, and 3:1 in propylene syringes at 24(degrees)C. The physical properties of the mixtures were observed with the naked eye and under a microscope, and their pH was measured. The concentration of each drug in the mixture was evaluated using high-performance liquid chromatography. Results: None of the ropivacaine and dexamethasone mixtures showed macroscopic or microscopic crystal formation after 2 hours, and there were no significant changes in pH. The concentrations of the 2 drugs remained stable for up to 2 hours. In contrast, at least 10 mu m crystals were observed microscopically and macroscopically in all mixtures of ropivacaine and betamethasone; the ropivacaine concentration was reduced by > 10% after one hour. Limitations: Confirming the stability of drugs in vitro does not ensure that their pharmacokinetics and pharmacodynamics remain unaltered in vivo. Conclusion: The combination of ropivacaine and betamethasone should be avoided because of their physicochemical instability. Combinations of ropivacaine and dexamethasone should be administered cautiously because they are more physicochemically stable than combinations of ropivacaine and betamethasone.
- Open Access
- 24 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (47) , e35042
Risk factors for new vertebral compression fracture after vertebroplasty and efficacy of osteoporosis treatment: A STROBE-compliant retrospective study
Vertebroplasty (VP) effectively treats vertebral compression fractures (VCFs). However, the issue of secondary new VCFs (SNVCFs) after VP is yet to be addressed. Therefore, identification of risk factors for SNVCFs after VP may aid the development of strategies to minimize SNVCF risk. This study aimed to retrospectively evaluate risk factors for SNVCFs after VP, including those associated with the type of anti-osteoporotic treatment administered after VP. Data from 128 patients who underwent single-level VP were collected and reviewed. Patients were divided into 2 groups: those with (n = 28) and without (n = 100) SNVCF within 1 year of VP. We collected the following patient data: age, sex, site of compression fracture, medical history, bone mineral density (BMD), history of long-term steroid use, history of osteoporosis drug use, duration between fracture and VP, VP implementation method (unilateral or bilateral), cement usage in VP, cement leakage into the disc, compression ratio before VP, pre- and postoperative recovery ratio of the lowest vertebral body height, and kyphotic angle of fractured vertebrae. These data were analyzed to identify factors associated with SNVCFs after VP and to investigate the effects of the type of anti-osteoporotic treatment administered for SNVCFs. SNVCFs occurred in 28 patients (21.9%) within 1 year of VP. Logistic regression analysis identified BMD, cement leakage into the disc, and long-term steroid use to be significantly associated with the occurrence of SNVCFs. The group treated with zoledronate after VP had a significantly reduced SNVCF incidence compared with the group treated with calcium (P < .001). In addition, the zoledronate group had a lower SNVCF incidence compared with the groups treated with alendronate (P = .05), selective estrogen receptor modulators (P = .26), or risedronate (P = .22). This study showed that low BMD, presence of an intradiscal cement leak, and long-term steroid use were risk factors for developing SNVCFs following VP. Additionally, among osteoporosis treatments prescribed for VP, zoledronate may be the preferred choice to reduce the risk of SNVCFs.
- 24 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (47) , e35042
Open AccessRisk factors for new vertebral compression fracture after vertebroplasty and efficacy of osteoporosis treatment: A STROBE-compliant retrospective study
Vertebroplasty (VP) effectively treats vertebral compression fractures (VCFs). However, the issue of secondary new VCFs (SNVCFs) after VP is yet to be addressed. Therefore, identification of risk factors for SNVCFs after VP may aid the development of strategies to minimize SNVCF risk. This study aimed to retrospectively evaluate risk factors for SNVCFs after VP, including those associated with the type of anti-osteoporotic treatment administered after VP. Data from 128 patients who underwent single-level VP were collected and reviewed. Patients were divided into 2 groups: those with (n = 28) and without (n = 100) SNVCF within 1 year of VP. We collected the following patient data: age, sex, site of compression fracture, medical history, bone mineral density (BMD), history of long-term steroid use, history of osteoporosis drug use, duration between fracture and VP, VP implementation method (unilateral or bilateral), cement usage in VP, cement leakage into the disc, compression ratio before VP, pre- and postoperative recovery ratio of the lowest vertebral body height, and kyphotic angle of fractured vertebrae. These data were analyzed to identify factors associated with SNVCFs after VP and to investigate the effects of the type of anti-osteoporotic treatment administered for SNVCFs. SNVCFs occurred in 28 patients (21.9%) within 1 year of VP. Logistic regression analysis identified BMD, cement leakage into the disc, and long-term steroid use to be significantly associated with the occurrence of SNVCFs. The group treated with zoledronate after VP had a significantly reduced SNVCF incidence compared with the group treated with calcium (P < .001). In addition, the zoledronate group had a lower SNVCF incidence compared with the groups treated with alendronate (P = .05), selective estrogen receptor modulators (P = .26), or risedronate (P = .22). This study showed that low BMD, presence of an intradiscal cement leak, and long-term steroid use were risk factors for developing SNVCFs following VP. Additionally, among osteoporosis treatments prescribed for VP, zoledronate may be the preferred choice to reduce the risk of SNVCFs.
- Open Access
Percutaneous Vertebroplasty in a Patient with Chronic Back Pain Caused by Multiple Schmorl’s Nodes: A Case Report
Background and Objectives: Schmorl’s nodes (SNs), formed by the herniation of intervertebral discs into adjacent vertebral bodies, are generally asymptomatic and do not require treatment. However, certain types of SNs can cause intractable back pain. Case Presentation: A 63-year-old man presented to our hospital with back pain after a fall 1 month prior. Physical examination revealed back pain that worsened with movement and paraspinal tenderness. Magnetic resonance imaging (MRI) performed immediately after presentation revealed subacute to chronic compression fractures with SNs at the upper endplates of the 11th and 12th thoracic and 1st lumbar vertebrae. Pain (numeric rating scale (NRS), 7–8/10) persisted despite 6 months of conservative treatment and MRI revealed increased signal intensity in T2-weighted images in the regions around the SNs. Based on these findings, an epidural nerve block was performed, and then repeated; however, no significant improvement was observed. Percutaneous vertebroplasty (PVP) was performed at the 11th and 12th thoracic and 1st lumbar vertebrae. Pain levels decreased substantially 1 week after PVP (NRS, 3–4/10). Subsequent treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and steroids for two weeks further reduced pain levels (NRS, 1–2/10), following which steroid use was discontinued and NSAID use became intermittent. At the six-month follow-up, pain levels remained low and the patient reported an improvement in activity levels of 90% or more. Conclusions: This case report demonstrates that PVP safely and effectively improved symptoms in a patient with multiple SNs and intractable back pain. Nevertheless, further research, particularly large-scale randomized prospective studies, is necessary to validate the long-term efficacy and safety of this intervention.
Open AccessPercutaneous Vertebroplasty in a Patient with Chronic Back Pain Caused by Multiple Schmorl’s Nodes: A Case Report
Background and Objectives: Schmorl’s nodes (SNs), formed by the herniation of intervertebral discs into adjacent vertebral bodies, are generally asymptomatic and do not require treatment. However, certain types of SNs can cause intractable back pain. Case Presentation: A 63-year-old man presented to our hospital with back pain after a fall 1 month prior. Physical examination revealed back pain that worsened with movement and paraspinal tenderness. Magnetic resonance imaging (MRI) performed immediately after presentation revealed subacute to chronic compression fractures with SNs at the upper endplates of the 11th and 12th thoracic and 1st lumbar vertebrae. Pain (numeric rating scale (NRS), 7–8/10) persisted despite 6 months of conservative treatment and MRI revealed increased signal intensity in T2-weighted images in the regions around the SNs. Based on these findings, an epidural nerve block was performed, and then repeated; however, no significant improvement was observed. Percutaneous vertebroplasty (PVP) was performed at the 11th and 12th thoracic and 1st lumbar vertebrae. Pain levels decreased substantially 1 week after PVP (NRS, 3–4/10). Subsequent treatment with non-steroidal anti-inflammatory drugs (NSAIDs) and steroids for two weeks further reduced pain levels (NRS, 1–2/10), following which steroid use was discontinued and NSAID use became intermittent. At the six-month follow-up, pain levels remained low and the patient reported an improvement in activity levels of 90% or more. Conclusions: This case report demonstrates that PVP safely and effectively improved symptoms in a patient with multiple SNs and intractable back pain. Nevertheless, further research, particularly large-scale randomized prospective studies, is necessary to validate the long-term efficacy and safety of this intervention.
- Open Access
- 9 December 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (49) , e32018
Risk factors for new vertebral compression fracture after kyphoplasty and efficacy of osteoporosis treatment: A STROBE-compliant retrospective study
Kyphoplasty (KP) has been widely used to treat vertebral compression fractures (VCFs). However, the issue of new VCFs after KP remains controversial. Identification of risk factors for new VCF after KP may help prevent their occurrence in patients. This study aimed to retrospectively determine the major risk factors for new VCF after KP, including those associated with osteoporosis drugs used after kyphoplasty. We reviewed 117 patients who underwent single-level KP. During the follow-up period of 1 year after KP, the demographic data of these patients were compared by dividing them into two groups: those with new fractures (n = 19) and those without new fractures (n = 98). We investigated the age, sex, fracture location, medical history, steroid use history, bone mineral density (BMD), type of osteoporosis treatment, period from fracture to KP, KP method (unilateral or bilateral), bone cement dose, intradiscal cement leakage, preoperative and postoperative compression ratio, kyphotic angle (KA), and lowest vertebral body height in the fractured vertebrae. Based on these data, the factors related to new VCFs after KP were investigated using univariate and multivariate logistic regression analyses. We also investigated whether there were differences in new VCFs according to the type of osteoporosis treatment. During the 1-year follow-up period after KP, the rate of new VCFs was 16.2%. Factors related to new VCFs were BMD, intradiscal cement leakage, KA recovery rate after 1 day, and baseline height in the univariate and multivariate logistic regression analyses. The group treated with zoledronate after KP tended to show a lower frequency of developing new VCFs than the groups treated with alendronate (P = .07), calcium (P = .05), selective estrogen receptor modulator (SERM) (P = .15), and risendronate (P = .02). This study showed that for patients with new VCFs after KP, lower BMD, greater intradiscal cement leakage, greater KA recovery rate, and lower baseline vertebral height were likely risk factors for the development of new VCFs. Additionally, among the drugs used for the treatment of osteoporosis after KP, zoledronate tends to reduce the development of new VCFs compared with other bisphosphonates, SERMs, or calcium.
- 9 December 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (49) , e32018
Open AccessRisk factors for new vertebral compression fracture after kyphoplasty and efficacy of osteoporosis treatment: A STROBE-compliant retrospective study
Kyphoplasty (KP) has been widely used to treat vertebral compression fractures (VCFs). However, the issue of new VCFs after KP remains controversial. Identification of risk factors for new VCF after KP may help prevent their occurrence in patients. This study aimed to retrospectively determine the major risk factors for new VCF after KP, including those associated with osteoporosis drugs used after kyphoplasty. We reviewed 117 patients who underwent single-level KP. During the follow-up period of 1 year after KP, the demographic data of these patients were compared by dividing them into two groups: those with new fractures (n = 19) and those without new fractures (n = 98). We investigated the age, sex, fracture location, medical history, steroid use history, bone mineral density (BMD), type of osteoporosis treatment, period from fracture to KP, KP method (unilateral or bilateral), bone cement dose, intradiscal cement leakage, preoperative and postoperative compression ratio, kyphotic angle (KA), and lowest vertebral body height in the fractured vertebrae. Based on these data, the factors related to new VCFs after KP were investigated using univariate and multivariate logistic regression analyses. We also investigated whether there were differences in new VCFs according to the type of osteoporosis treatment. During the 1-year follow-up period after KP, the rate of new VCFs was 16.2%. Factors related to new VCFs were BMD, intradiscal cement leakage, KA recovery rate after 1 day, and baseline height in the univariate and multivariate logistic regression analyses. The group treated with zoledronate after KP tended to show a lower frequency of developing new VCFs than the groups treated with alendronate (P = .07), calcium (P = .05), selective estrogen receptor modulator (SERM) (P = .15), and risendronate (P = .02). This study showed that for patients with new VCFs after KP, lower BMD, greater intradiscal cement leakage, greater KA recovery rate, and lower baseline vertebral height were likely risk factors for the development of new VCFs. Additionally, among the drugs used for the treatment of osteoporosis after KP, zoledronate tends to reduce the development of new VCFs compared with other bisphosphonates, SERMs, or calcium.
- Open Access
Spinal Cord Injury and Postdural Puncture Headache following Cervical Interlaminar Epidural Steroid Injection: A Case Report
Background: Cervical interlaminar epidural steroid injection (CIESI) is increasingly used as an interventional treatment for pain originating from the cervical spine. However, serious neurological complications may occur during CIESI because of direct nerve damage following inappropriate needle placement. Case report: A 35-year-old woman presented with posterior neck pain radiating to the left upper arm. Cervical magnetic resonance imaging (MRI) revealed left C6 nerve impingement. CIESI under fluoroscopic guidance was performed at another hospital using the left C5/6 interlaminar approach. Immediately after the procedure, the patient experienced dizziness, decreased blood pressure, motor weakness in the left upper arm, and sensory loss. She visited our emergency department with postdural puncture headache (PDPH) that worsened after the procedure. Post-admission cervical MRI revealed intramedullary T2 high signal intensity and cord swelling from the C4/5 to C6/7 levels; thus, a diagnosis of spinal cord injury was made. The patient’s PDPH spontaneously improved after 48 h. However, despite conservative treatment with steroids, the decrease in abduction of the left fifth finger and loss of sensation in the dorsum of the left hand persisted for up to 6 months after the procedure. As noticed in the follow-up MRI performed 6 months post-procedure, the T2 high signal intensity in the left intramedullary region had decreased compared to that observed previously; however, cord swelling persisted. Furthermore, left C7/8 radiculopathy with acute denervation was confirmed by electromyography performed 6 months after the procedure. Conclusions: Fluoroscopy does not guarantee the prevention of spinal cord penetration during CIESI. Moreover, persistent neurological deficits may occur, particularly due to intrathecal perforation or drug administration during CIESI. Therefore, in accordance with the recommendations of the Multisociety Pain Workgroup, we recommend performing CIESI at the C6/7 or C7/T1 levels, where the epidural space is relatively large, rather than at the C5/6 level or higher.
Open AccessSpinal Cord Injury and Postdural Puncture Headache following Cervical Interlaminar Epidural Steroid Injection: A Case Report
Background: Cervical interlaminar epidural steroid injection (CIESI) is increasingly used as an interventional treatment for pain originating from the cervical spine. However, serious neurological complications may occur during CIESI because of direct nerve damage following inappropriate needle placement. Case report: A 35-year-old woman presented with posterior neck pain radiating to the left upper arm. Cervical magnetic resonance imaging (MRI) revealed left C6 nerve impingement. CIESI under fluoroscopic guidance was performed at another hospital using the left C5/6 interlaminar approach. Immediately after the procedure, the patient experienced dizziness, decreased blood pressure, motor weakness in the left upper arm, and sensory loss. She visited our emergency department with postdural puncture headache (PDPH) that worsened after the procedure. Post-admission cervical MRI revealed intramedullary T2 high signal intensity and cord swelling from the C4/5 to C6/7 levels; thus, a diagnosis of spinal cord injury was made. The patient’s PDPH spontaneously improved after 48 h. However, despite conservative treatment with steroids, the decrease in abduction of the left fifth finger and loss of sensation in the dorsum of the left hand persisted for up to 6 months after the procedure. As noticed in the follow-up MRI performed 6 months post-procedure, the T2 high signal intensity in the left intramedullary region had decreased compared to that observed previously; however, cord swelling persisted. Furthermore, left C7/8 radiculopathy with acute denervation was confirmed by electromyography performed 6 months after the procedure. Conclusions: Fluoroscopy does not guarantee the prevention of spinal cord penetration during CIESI. Moreover, persistent neurological deficits may occur, particularly due to intrathecal perforation or drug administration during CIESI. Therefore, in accordance with the recommendations of the Multisociety Pain Workgroup, we recommend performing CIESI at the C6/7 or C7/T1 levels, where the epidural space is relatively large, rather than at the C5/6 level or higher.